QUANTITATION OF ESCHERICHIA-COLI PROTEIN IMPURITIES IN RECOMBINANT HUMAN INTERFERON-GAMMA

被引:13
作者
CHEN, AB
CHAMPIONSMITH, AA
BLANCHARD, J
GORRELL, J
NIEPELT, BA
FEDERICI, MM
FORMENTO, J
SINICROPI, DV
机构
[1] GENENTECH INC,DEPT MED & ANALYT CHEM,M-S 38,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080
[2] GENENTECH INC,DEPT PROC SCI,S SAN FRANCISCO,CA 94080
[3] GENENTECH INC,DEPT QUAL CONTROL,S SAN FRANCISCO,CA 94080
关键词
INTERFERON-GAMMA; IMPURITY ASSAYS; ESCHERICHIA-COLI PROTEINS; PROTEIN INTERACTIONS; RECOMBINANT PROTEINS;
D O I
10.1007/BF02929693
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A multiple antigen ELISA for E. coli proteins (ECPs) that may be present in purified recombinant human interferon-gamma (rIFN-gamma) was developed. SDS-PAGE and Western blotting analyses showed that the assay antibodies reacted with a wide spectrum of ECPs in the standard and with ECPs in a production run. In spike recovery studies, rIFN-gamma at concentrations of 0.05 mg/mL and higher augmented the immunoreactivity of the ECPs in the standard curve (1.3-40.0 ng ECPs/mL) by approx 50%. To determine ECP content in purified rIFN-gamma, 0.2 mg/mL of rIFN-gamma was added to the standard curve diluent to compensate for enhanced immunoreactivity. The assay was precise (interassay precision of ECP controls less-than-or-equal-to 4.1 %CV) and accurate with recoveries of 111-115% of expected for ECPs (15-40 ng/mL) spiked into purified rIFN-gamma (1 mg/mL). Linearity of dilution for ECPs spiked into rIFN-gamma was obtained (r = 0.999). Moreover, linearity of dilution was obtained for ECPs in "in-process" samples, demonstrating the required condition of antibody excess for this type of multiple antigen ELISA. ECPs were not detectable in several purified lots of rIFN-gamma. Therefore, these lots contained <1.3 ppm ECPs.
引用
收藏
页码:137 / 152
页数:16
相关论文
共 16 条
[2]   IMMUNOASSAY FOR THE DETECTION OF ESCHERICHIA-COLI PROTEINS IN RECOMBINANT-DNA DERIVED HUMAN GROWTH-HORMONE [J].
ANICETTI, VR ;
FEHSKENS, EF ;
REED, BR ;
CHEN, AB ;
MOORE, P ;
GEIER, MD ;
JONES, AJS .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 91 (02) :213-224
[3]   PURITY ANALYSIS OF PROTEIN PHARMACEUTICALS PRODUCED BY RECOMBINANT DNA TECHNOLOGY [J].
ANICETTI, VR ;
KEYT, BA ;
HANCOCK, WS .
TRENDS IN BIOTECHNOLOGY, 1989, 7 (12) :342-349
[4]  
BAKER RS, 1981, LANCET, V2, P1139
[5]  
CHEN AB, 1990, QUANTITATION CHINESE
[6]  
GOOD AH, 1980, SELECTED METHODS CEL, P278
[7]  
JONES AJS, 1988, IMPACT CHEM BIOTECHN, P193
[8]   CLEAVAGE OF STRUCTURAL PROTEINS DURING ASSEMBLY OF HEAD OF BACTERIOPHAGE-T4 [J].
LAEMMLI, UK .
NATURE, 1970, 227 (5259) :680-+
[9]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265
[10]   ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISAS) FOR THE DETERMINATION OF CONTAMINANTS RESULTING FROM THE IMMUNOAFFINITY PURIFICATION OF RECOMBINANT PROTEINS [J].
LUCAS, C ;
NELSON, C ;
PETERSON, ML ;
FRIE, S ;
VETTERLEIN, D ;
GREGORY, T ;
CHEN, AB .
JOURNAL OF IMMUNOLOGICAL METHODS, 1988, 113 (01) :113-122